By Daniel R. Matlis
The Life-Sciences industry is undergoing a metamorphosis. Historically separate disciplines, like pharmaceuticals, devices, diagnostics, biotech, and even nanotech, are converging.
This trend will accelerate as personalized medicine and genetic therapies evolve. In the not to distant future, your Doctor will be able to target specific medical treatments to address your condition based on your unique DNA.
This shift to convergence medicine is already underway with the combination of traditional pharmaceuticals and medical devices. Products like drug coated stents and antibacterial sutures are breaking down the traditional barriers in healthcare.
Today, pharmaceutical companies are looking to biotech firms for innovation and new ways to treat conditions.
Read more about this trend and my opinion on it in Chemicals to Cell Culture published in this month’s issue of Intech Magazine.